Medtronic (MDT) Stock Forecast & Price Target

$94.12 -0.05 (-0.05%)

As of 09/4/2026 03:58 PM Eastern

Compare

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
0

Hold
9

Buy
19

Based on 28 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 9 have given a hold rating, and 19 have given a buy rating for MDT.

Consensus Price Target

$103.92
10.41% Upside

According to the 28 analysts' twelve-month price targets for Medtronic, the average price target is $103.92. The highest price target for MDT is $120.00, while the lowest price target for MDT is $83.00. The average price target represents a forecasted upside of 10.41% from the current price of $94.12.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	19 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	9 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	11 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$103.92	$98.83	$99.00	$102.14
Forecasted Upside	10.41% Upside	13.42% Upside	23.34% Upside	9.94% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medtronic Stock vs. The Competition

Type	Medtronic	Healthcare Companies	Broader Market
Consensus Rating Score	2.68	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	10.41% Upside	928.67% Upside	14.03% Upside
News Sentiment Rating	Positive News See Recent MDT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/4/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
9/3/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Reiterated Rating	Hold	$92.00	-0.04%
9/3/2026	UBS Group 4 of 5 stars	Priya Sachdeva Not Rated	Boost Target	Buy	$100.00 ➝ $110.00	+19.43%
9/2/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$115.00	+24.86%
9/2/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bob Hopkins Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$95.00 ➝ $110.00	+19.67%
9/2/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$102.00 ➝ $104.00	+13.14%
9/2/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$86.00 ➝ $99.00	+7.70%
9/2/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$118.00	+28.37%
9/2/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$91.00 ➝ $100.00	+8.79%
9/2/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$80.00 ➝ $95.00	+3.35%
They're not buying gold. They're buying this. (Ad) Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices. See the name, ticker, and full file now
9/1/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$91.00 ➝ $100.00	+8.10%
8/28/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $110.00	+22.17%
8/27/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$101.00 ➝ $114.00	+23.70%
8/10/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$105.00	+27.49%
6/5/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$111.00 ➝ $106.00	+28.58%
6/4/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$112.00 ➝ $97.00	+17.46%
6/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$88.00	+12.70%
6/4/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$100.00 ➝ $86.00	+4.07%
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$84.00 ➝ $83.00	+0.55%
6/4/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$117.00 ➝ $104.00	+33.19%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$117.00 ➝ $110.00	+27.75%
4/6/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$125.00 ➝ $115.00	+32.76%
4/1/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$118.00 ➝ $120.00	+39.57%
2/27/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$117.00 ➝ $115.00	+17.83%
1/30/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
1/6/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Vazquez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
11/19/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$107.00 ➝ $117.00	+16.20%
6/30/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:23 AM ET.

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 5, 2026. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

Here are some ways that investors could benefit from investing in Medtronic plc:

Medtronic plc recently reported strong financial results for the quarter ended September 1, 2026, beating analyst expectations with earnings per share of $1.45 compared to a consensus estimate of $1.39, while revenue of $9.76 billion exceeded the expected $9.55 billion, demonstrating robust fundamental performance and a 13.7% year-over-year revenue increase.
The stock is currently trading at $94.12, which is below the average analyst price target of $98.83 as of August 21, 2026, suggesting potential upside for investors as the consensus rating remains a Moderate Buy with 19 analysts issuing Buy ratings versus nine Hold ratings.
Medtronic plc offers a dividend yield of 3.09%, with a recent quarterly dividend of $0.72 per share declared for payment on October 16, 2026, providing a steady income stream for investors despite a payout ratio of 70.94%.
New real-world evidence from the PERSIST addendum study is supporting the company's Inceptiv spinal cord stimulation system, which could improve adoption prospects and strengthen the pain-management franchise, adding a positive catalyst for the Neuroscience Portfolio segment.
Institutional investors are showing renewed interest, with Oakmont Investment Advisors Inc. acquiring a new stake of 26,858 shares valued at approximately $2.10 million in the second quarter, and NEOS Investment Management LLC boosting its holdings by 9.7%, indicating growing confidence among professional investors.

Medtronic
Bear Case

Investors should be bearish about investing in Medtronic plc for these reasons:

A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains, which raises the risk of profit-taking or volatility despite the positive fundamental backdrop.
Wall Street Zen downgraded Medtronic from a Buy rating to a Hold rating on September 5, 2026, reflecting a more cautious outlook from at least one analyst firm, which could signal a shift in sentiment among some market participants.
Short interest in Medtronic shares increased to 14,350,429 shares as of August 14, 2026, representing a 1.12% short percentage of float, indicating that some investors are betting against the stock's future performance, although the days to cover is relatively low at 2.25.
Insider selling activity has been notable, with EVP Harry Skip Kiil selling 4,189 shares at an average price of $80.44 on June 8, 2026, and previously selling 52,524 shares at $97.71 on February 19, 2026, which may raise concerns about executive confidence in the stock's near-term valuation.
The company's debt-to-equity ratio stands at 0.52, and while the current ratio is healthy at 2.13, the high payout ratio of 70.94% for dividends could limit flexibility for future capital expenditures or share buybacks if revenue growth slows.

MDT Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $103.92, with a high forecast of $120.00 and a low forecast of $83.00.

28 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 9 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 10.41% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 2 upgrades by analysts.

Medtronic has been rated by research analysts at Bank of America, BTIG Research, Deutsche Bank Aktiengesellschaft, Evercore, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Medtronic more than other "healthcare" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MDT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

MarketBeat monitors more than a dozen sources for Medtronic analyst ratings, with the most recent rating issued on 9/4/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medtronic (MDT) Stock Forecast & Price Target

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MDT Analyst Ratings Over Time

MDT Analyst Recommendations By Month

MDT Price Targets by Month

Medtronic Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

Medtronic
Bull Case

Medtronic
Bear Case

MDT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medtronic (MDT) Stock Forecast & Price Target

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MDT Analyst Ratings Over Time

MDT Analyst Recommendations By Month

MDT Price Targets by Month

Medtronic Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

Medtronic Bull Case

Medtronic Bear Case

MDT Forecast - Frequently Asked Questions

What is Medtronic's forecast for 2026?

Should I buy or sell Medtronic stock right now?

Does Medtronic's stock price have much upside?

Has Medtronic been upgraded by Wall Street analysts recently?

What analysts cover Medtronic?

Do Wall Street analysts like Medtronic more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Medtronic
Bull Case

Medtronic
Bear Case